Bioequivalence Study of Levomerc (Levofloxacin) 500 mg Tablet With Tavanic (Levofloxacin) 500 mg Tablets
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- maximum plasma concentration
研究概览
简要总结
An open Label, Randomized, Two Way Cross over, Two Period, Two Treatment, two Sequence Bioequivalence Study of Levomerc tablets (Levofloxacin) 500 mg compared with Tavanic (Levofloxacin) 500 mg Tablet as reference drug in healthy Pakistani subjects under fasting condition.
详细描述
The study will be conducted on 24 healthy subjects. The study will comprise of two Periods, I and II, each consisting of 36 hours, 12 hours before and 24 hour after the drug administration. All 24 subjects divided in group of 12 each. One group treated with the test (T) and other one with reference (R) drug in Period I and after the wash out period, the same received the alternate treatment in Period II.
blood samples will be collected for up to 24 hours post dose in each period for plasma analysis of Levofloxacin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects should be healthy and free from any epidemic, contagious or measurable disease (e.g. Malaria, Dengue).
- •Age range for inclusion will be 18-50 year.
- •BMI for all Subjects will be between 18.5-26.9 kg/ m
- •Non Smokers, who have not smoked in last 3 months.
- •Medical history, physical examination and screening tests must fall in normal range, unless the investigator considers the abnormality to be clinically not significant.
- •Clinical laboratory test result should be within a normal range.
- •Participants (who can read and understand Urdu) should be able to give informed consent, understand and sign the Informed Consent Form.
- •Participants should have adequate organ function (i.e., kidney, liver and heart).
排除标准
- •Age and/or BMI out of acceptable range.
- •Any active allergic disease or a history of any significant allergic disease (e.g. Rhinitis, dermatitis, asthma).
- •Known hypersensitivity to Investigational drug(s).
- •Abnormal results of blood and urine tests conducted at screening unless the investigator considers an abnormality to be clinically irrelevant.
- •Presence or history of cardiac (e.g. Myocardial Infarction, arrythmia), renal (e.g. renal insufficiency) , hepatic (e.g. hepatic impairment) , organ insufficiency, bone marrow disease, hematological abnormality (e.g. leukemia, anemia), photosensitivity, neurological disorders (e.g. Alzheimer's disease) or gastrointestinal disease known to interfere with the drug absorption, distribution, metabolism or elimination (e.g. dysphagia).
- •History or presence of any musculo skeletal disease (e.g. Tendonitis).
- •Subject donated blood (450ml) within 12 weeks minimum preceding the study.
- •Alcoholic or with a history of chronic alcohol intake or consumed alcohol or Gutka in last 3 months.
- •Ingestion of OTC drug, within 14 days of drug administration (e.g. aspirin, ibuprofen).
- •History of intake of any prescribed medicine (e.g. captopril, sumatriptan) during a period of 30 days, prior to drug administration day of study.
- •Ingestion of investigational drug within 30 days, prior to investigational drug administration in the study.
- •Ingestion of any known hepatic or renal clearance altering agents (e.g. erythromycin, cimetidine, barbiturates, phenothiazines, etc.) for a period of 30 days, prior to study initiation.
- •Subjects with an uncontrolled medical condition (i.e., hypertension, cardiac arrhythmias, CHF) that places the patient at risk by participating in the study.
- •xiv. Subjects with known HIV, hepatitis B or C infection or autoimmune diseases.
- •History of drug exposure which, in the opinion of Investigator, amounts to drug abuse. -
- •Participation in other drug studies within three months prior to study initiation.
- •Subjects with any physical/mental disability.
- •Limited mental capacity to the extent that the subject is unable to provide legal consent and information regarding the side effects or tolerance of the study drug.
- •Pregnancy or breast feeding, women of child bearing age who are not using a recognized form of contraception for at least last 30 days or using hormonal contraception, are also excluded.
研究组 & 干预措施
Test Group
Levomerc (Levofloxacin) tablets 500 mg
干预措施: Levofloxacin 500mg (Drug)
Reference Group
Tavanic (Levofloxacin) tablets 500 mg
干预措施: Levofloxacin 500mg (Drug)
结局指标
主要结局
maximum plasma concentration
时间窗: up to 24 hours post dose
maximum drug concentration in plasma after dose
Time to reach maximum plasma concentration
时间窗: 0 to 24 hours post dose
Time required for the drug to reach maximum plasma concentration
AUC
时间窗: 0-2 4hours
Area under the time versus plasma drug concentration curve
次要结局
未报告次要终点
研究者
Dr. Muhammad Raza Shah
Professor
University of Karachi